Neurology Minute
In part one of this two-part series, Dr. Stacey Clardy and Dr. Elia Sechi discuss the clinical scenarios where the commonly used assay for myasthenia gravis is most likely to produce false positive results in patients who do not actually have myasthenia gravis. Show reference:
info_outlineNeurology Minute
Dr. Roy E. Strowd and Dr. Susannah Cornes discuss a teaching incentive initiative designed to support and reward faculty in academic neurology. Show reference:
info_outlineNeurology Minute
In the first installment of this three-part series, Dr. Elizabeth Zollos explores how optical coherence tomography is advancing our understanding of multiple sclerosis and enhancing diagnostic accuracy.
info_outlineNeurology Minute
In part two of this two-part series, Dr. Jeff Ratliff and Dr. Per Borghammer explore the subcategories of Lewy body disease, focusing on the body-first subtype Show reference:
info_outlineNeurology Minute
In the second installment of this two-part series, Dr. Stacey Clardy and Dr. Janis Miyasaki discuss how she got involved with the AAN. Show reference:
info_outlineNeurology Minute
In part one of this two-part series, Dr. Jeff Ratliff and Dr. Per Borghammer examine the dichotomy that existed before his team began this project. Show reference:
info_outlineNeurology Minute
In the first installment of this two-part series, Dr. Stacey Clardy engages in a thought-provoking conversation with Dr. Janis Miyasaki, asking her to share two invaluable pieces of wisdom. Show reference:
info_outlineNeurology Minute
Dr. Jeff Lambe talks about progressive multiple sclerosis. Show references:
info_outlineNeurology Minute
Dr. Justin Abbatemarco discuss autoimmune encephalitis with a focus on outcomes. Show reference:
info_outlineNeurology Minute
In part two of this two-part series, Dr. Dan Ackerman and Dr. Trey Bateman discuss handling patient requests for blood-based biomarkers for Alzheimer disease and interpreting test results.
info_outlineIn part one of this three-part series, Dr. Justin Abbatemarco and Dr. Jiwon Oh discuss how Bruton Tyrosine Kinase (BTK) Inhibitors work and how they vary from other disease-modifying therapies.
Show reference: